Aldosterone receptor antagonists: Current perspectives and therapies

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 321-331

  Guichard, Jason L ^a   Clark III, Donald ^a   Calhoun, David A ^a   Ahmed, Mustafa I ^a  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

Aldosterone antagonist; Chronic kidney disease; Heart failure; Hypertension; Mineralocorticoid receptor antagonist; Obstructive sleep apnea; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANRENOATE POTASSIUM; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACEBO; SPIRONOLACTONE; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADVERSE OUTCOME; ALDOSTERONE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIRSUTISM; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; IMPOTENCE; LIBIDO DISORDER; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; METABOLIC ACIDOSIS; NEPHROTIC SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; RESISTANT HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDERED BREATHING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; VAGINA BLEEDING;

ALDOSTERONE ANTAGONIST; CHRONIC KIDNEY DISEASE; HEART FAILURE; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONIST; OBSTRUCTIVE SLEEP APNEA; PRIMARY ALDOSTERONISM;

ALDOSTERONE; ANIMALS; HEART FAILURE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SLEEP APNEA, OBSTRUCTIVE;

EID: 84880615159     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S33759     Document Type: Review

References (90)

1. Funder J W. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology. 2010;151(11):5098-5102.
2. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocor-ticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012.
3. Funder J W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology. 2006;147(12):5564-5567.
4. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
5. Witham MD, Gillespie ND, Struthers AD. Hyperkalemia after the publication of RALES. N Engl J Med. 2004;351(23):2448-2450; author reply 2448-2450.
6. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33(22):2782-2795.
7. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46(5):845-849.
8. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118(16):1643-1650.
9. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/ AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
10. Pisoni R, Acelajado MC, Cartmill FR, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26(8):502-506.
11. Vardeny O, Wu DH, Desai A, et al. Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure: Insights From RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60(20):2082-2089.
12. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820-828.
13. Funder J W, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-3281.
14. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165.
15. Rossi G P, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40(1):23-27.
16. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension. 2008;52(3): 529-534.
17. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 19, 2005;45(8):1243-1248.
18. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80-85.
19. Born-Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009;94(4):1125-1130.
20. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50(5):911-918.
21. Catena C, Colussi G, Di Fabio A, et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res. 2010;42(6):440-445.
22. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41.
23. Rossi G P, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300.
24. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892-896.
25. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofeld SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453-459.
26. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820-825.
27. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709-716.
28. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eple-renone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41(7):1148-1155.
29. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40(2):117-123.
30. Sato A, Takane H, Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res. 2001;24(2):99-104.
31. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831-1838.
32. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorti-coid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51(2):432-439.
33. Leenen FH, Ruzicka M, Floras JS. Central sympathetic inhibition by min-eralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low? Hypertension. 2012;60(2):278-280.
34. Kontak AC, Wang Z, Arbique D, et al. Reversible sympathetic over-activity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95(10):4756-4761.
35. Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60(2):319-325.
36. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.
37. Kumbhani DJ, Steg PG, Cannon C P, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2012.
38. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37(4):699-705.
39. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17(5):349-352.
40. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217-2226.
41. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159-1164.
42. Gaddam K, Corros C, Pimenta E, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55(5):1137-1142.
43. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925-930.
44. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845.
45. De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolac-tone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147-152.
46. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28(11):2329-2335.
47. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283(14):1829-1836.
48. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271-2277.
49. Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363-368.
50. Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532-537.
51. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689-1697.
52. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9(1):145-149.
53. Jorde U P, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002;106(9):1055-1057.
54. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
55. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival beneft of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102(22):2700-2706.
56. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321.
57. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with frst anterior acute myocardial infarction. Circulation. 2003;107(20):2559-2565.
58. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. January 6, 2011;364(1):11-21.
59. Rogers JK, McMurray JJ, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126(19):2317-2323.
60. Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 2002;40(5):647-652.
61. Boccanelli A, Mureddu G F, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): fnal results. Eur J Heart Fail. 2009;11(1):68-76.
62. Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160(4):642-648.
63. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58(19):1958-1966.
64. Albert NM, Yancy C W, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302(15):1658-1665.
65. Samuel JL, Delcayre C. Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol. 2010;7(3):125-127.
66. Rassi AN, Cavender MA, Fonarow GC, et al. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2012.
67. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011;161(6): 1024-1030. e1023.
68. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585-596.
69. Mohammed SF, Ohtani T, Korinek J, et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation. 2010;122(4):370-378.
70. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110(5):558-565.
71. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54(18):1674-1682.
72. Edwards NC, Ferro CJ, Kirkwood H, et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010;106(10):1505-1511.
73. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634-642.
74. Edelmann FWR, Schmidt AG, et al. Effect of spironolactone on dia-stolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781-791.
75. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162(6):966-972. e910.
76. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295(22):2638-2645.
77. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119(11):912-919.
78. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010;362(1):56-65.
79. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldos-terone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41(5):1021-1026.
80. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31(1):59-67.
81. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3): 542-551.
82. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microal-buminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012;29(8):e184-e190.
83. Edwards NC, Steeds R P, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012; 73(3):447-454.
84. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012;81(10):955-968.
85. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorti-coid receptor: prospects for novel therapeutics. Mol Cell Endocrinol. 24, 2012;350(2):310-317.
86. Beermann B, Groschinsky-Grind M. Clinical pharmacokinetics of diuretics. Clin Pharmacokinet. 1980;5(3):221-245.
87. Ho PC, Bourne DW, Triggs EJ, Heazlewood V. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone. Eur J Clin Pharmacol. 1984;27(4):441-446.
88. Overdiek HW, Hermens WA, Merkus F W. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985;38(4): 469-474.
89. Cook CS, Zhang L, Fischer JS. Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. Pharm Res. 2000;17(11):1426-1431.
90. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu N W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31(11): 1448-1455.